newsfilter
← Latest News
PR Newswire·

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

LEXINGTON, Mass., June 15, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and central nervous system